共 4 条
- [2] Reply to Charles B. Simone II, Charles B. Simone's Letter to the Editor re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. Eur Urol 2011;59:88-95 EUROPEAN UROLOGY, 2011, 59 (05) : E31 - E32
- [3] Reply to Aaron M. Potretzke, Jeffrey A. Larson and Sam B. Bhayani's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015; 67: 252-9 EUROPEAN UROLOGY, 2015, 67 (02) : E21 - E22
- [4] Reply to Alberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R. Jeffrey Karnes, and Francesco Montorsi's Letter to the Editor re: Jean FP Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Eur Urol 2021;79:595-604. Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performing Extended Pelvic Lymph Node Dissection in Selected Patients with Prostate Cancer EUROPEAN UROLOGY, 2021, 79 (06) : E184 - E185